Y-mAbs Therapeutics Inc (YMAB)
12.85
+0.29
(+2.31%)
USD |
NASDAQ |
May 22, 16:00
12.85
0.00 (0.00%)
After-Hours: 20:00
Y-mAbs Therapeutics Research and Development Expense (Quarterly): 13.27M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.27M |
| December 31, 2023 | 13.39M |
| September 30, 2023 | 15.36M |
| June 30, 2023 | 12.06M |
| March 31, 2023 | 13.42M |
| December 31, 2022 | 19.79M |
| September 30, 2022 | 22.45M |
| June 30, 2022 | 26.42M |
| March 31, 2022 | 22.91M |
| December 31, 2021 | 28.76M |
| September 30, 2021 | 23.13M |
| June 30, 2021 | 19.78M |
| March 31, 2021 | 21.58M |
| December 31, 2020 | 24.01M |
| Date | Value |
|---|---|
| September 30, 2020 | 21.00M |
| June 30, 2020 | 30.06M |
| March 31, 2020 | 18.62M |
| December 31, 2019 | 16.83M |
| September 30, 2019 | 19.66M |
| June 30, 2019 | 14.49M |
| March 31, 2019 | 12.51M |
| December 31, 2018 | 11.04M |
| September 30, 2018 | 8.731M |
| June 30, 2018 | 8.293M |
| March 31, 2018 | 6.204M |
| December 31, 2017 | 6.625M |
| September 30, 2017 | 3.076M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.06M
Minimum
Jun 2023
30.06M
Maximum
Jun 2020
19.85M
Average
19.78M
Median
Research and Development Expense (Quarterly) Benchmarks
| The Cooper Companies Inc | 39.50M |
| Puma Biotechnology Inc | 13.59M |
| Humacyte Inc | 21.26M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |